Literature DB >> 11051216

Drug-induced rheumatic disorders: incidence, prevention and management.

P Vergne1, P Bertin, C Bonnet, C Scotto, R Trèves.   

Abstract

The purpose of this article is to review the causes, the clinical manifestations and the management of the more frequent drug-induced rheumatic disorders. These include: (i) articular and periarticular manifestations induced by fluoroquinolones, nonsteroidal anti-inflammatory drugs, injections of corticosteroids, and retinoids; (ii) multisystemic manifestations such as drug-induced lupus and arthritis induced by vaccination, Bacillus Calmette-Guerin therapy and cytokines; (iii) drug-induced disorders of bone metabolism (corticosteroid-induced osteoporosis, drug-induced osteomalacia and osteonecrosis); and (iv) iatrogenic complex regional pain syndromes. Disorders caused by nonpharmacological and rarely used treatments have been deliberately excluded. Knowledge of these drug-induced clinical symptoms or syndromes allows an earlier diagnosis and treatment, and earlier drug withdrawal if necessary. With the introduction of new medications such as the recombinant cytokines and antiretroviral treatments, the number of drug-induced rheumatic disorders is likely to increase.

Entities:  

Mesh:

Year:  2000        PMID: 11051216     DOI: 10.2165/00002018-200023040-00002

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  78 in total

1.  Reactivation of rheumatoid arthritis and development of leukocytoclastic vasculitis in a patient receiving granulocyte colony-stimulating factor for Felty's syndrome.

Authors:  B Vidarsson; A J Geirsson; P T Onundarson
Journal:  Am J Med       Date:  1995-06       Impact factor: 4.965

2.  Charcot's arthropathy of the shoulder following intraarticular corticosteroid injections.

Authors:  J R Parikh; J B Houpt; S Jacobs; B J Fernandes
Journal:  J Rheumatol       Date:  1993-05       Impact factor: 4.666

Review 3.  Quinolones in children. Are concerns over arthropathy justified?

Authors:  R Stahlmann; C Förster; D Van Sickle
Journal:  Drug Saf       Date:  1993-12       Impact factor: 5.606

4.  Histomorphometric analysis of a calcaneal stress fracture: a possible complication of fluoride therapy for osteoporosis.

Authors:  C M Schnitzler; L Solomon
Journal:  Bone       Date:  1986       Impact factor: 4.398

5.  Sodium monofluorophosphate increases vertebral bone mineral density in patients with corticosteroid-induced osteoporosis.

Authors:  R Rizzoli; T Chevalley; D O Slosman; J P Bonjour
Journal:  Osteoporos Int       Date:  1995-01       Impact factor: 4.507

6.  Rubella-associated arthritis. I. Comparative study of joint manifestations associated with natural rubella infection and RA 27/3 rubella immunisation.

Authors:  A J Tingle; M Allen; R E Petty; G D Kettyls; J K Chantler
Journal:  Ann Rheum Dis       Date:  1986-02       Impact factor: 19.103

7.  High-dose glucocorticoids in multiple sclerosis patients exert direct effects on the kidney and skeleton.

Authors:  F Cosman; J Nieves; J Herbert; V Shen; R Lindsay
Journal:  J Bone Miner Res       Date:  1994-07       Impact factor: 6.741

8.  [3 cases of polyarthritis treated with recombinant alfa interferon].

Authors:  P Chazerain; O Meyer; P Ribard; M De Bandt; C Mechelany; P Marcellin; J F Bernard; M Grossin; M F Kahn
Journal:  Rev Rhum Mal Osteoartic       Date:  1992-05

9.  Thyroiditis after treatment with interleukin-2 and interferon alpha-2a.

Authors:  G Pichert; L M Jost; L Zöbeli; B Odermatt; G Pedia; R A Stahel
Journal:  Br J Cancer       Date:  1990-07       Impact factor: 7.640

10.  Calcium metabolism during rifampicin and isoniazid therapy for tuberculosis.

Authors:  W Perry; M A Erooga; J Brown; T C Stamp
Journal:  J R Soc Med       Date:  1982-07       Impact factor: 18.000

View more
  3 in total

Review 1.  Environmental risk factors of systemic sclerosis.

Authors:  Isabelle Marie; Jean-François Gehanno
Journal:  Semin Immunopathol       Date:  2015-07-04       Impact factor: 9.623

2.  LE135, a retinoid acid receptor antagonist, produces pain through direct activation of TRP channels.

Authors:  Shijin Yin; Jialie Luo; Aihua Qian; Weihua Yu; Hongzhen Hu
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

Review 3.  Drug-induced musculoskeletal disorders.

Authors:  Bernard Bannwarth
Journal:  Drug Saf       Date:  2007       Impact factor: 5.228

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.